Abstract
Background
Although isolated calf muscular vein thrombosis (ICMVT) is commonly seen after hip and knee arthroplasty, no treatment guidelines for ICMVT after joint replacement are available. The purpose of this study was to evaluate the outcomes of patients with ICMVT for anticoagulant therapy at different time points after primary hip and knee arthroplasty.
Methods
Patients with ICMVT after primary hip and knee arthroplasty were included in the study. Diagnosis was established with Doppler ultrasound. Patients were followed up clinically and with Doppler ultrasound at 1, 2, and 3 months. The outcomes were efficacy (complete resolution) and acceptability (hemorrhagic events). Anticoagulant therapy at curative dosage was prescribed for 1 month and was extended for 2 additional months in case of incomplete resolution at 1 month or if propagation was present. The chi-square test was used to compare the outcomes at different time points.
Results
302 patients were taken hip and knee arthroplasty from January 2021 to May 2022, in which 51 patients presented with 51 ICMVTs postoperatively. The incidence of ICMVT was about 16.89%. Resolution of ICMVT was considered complete at 1, 2, and 3 months at 36.73%, 61.22%, and 91.84%, respectively, with significant differences among the time points (P < 0.05). All patients with ICMVT receiving anticoagulant therapy remained free of propagations and hemorrhagic events within 3 months.
Conclusion
Our findings provide new insights into the anticoagulant therapy for ICMVT after primary hip and knee arthroplasty, taking oral Rivaroxaban for 3 months is effective and safe, which contributes to provide the reference for clinical practice.
Similar content being viewed by others
Availability of data and materials
All data generated or analyzed during this study are included in this published article.
References
Zhuang Q, He Q, Aikebaier A, Chen W, Liu J, Wang D (2023) The risk factors for new-onset calf muscle venous thrombosis after hip fracture surgery. J Pers Med 13(2):257
Reich-Schupke S, Stücker M (2011) Nomenclature of the veins of the lower limbs - current standards. J Dtsch Dermatol Ges 9(3):189–194
Gillet JL, Perrin MR, Allaert FA (2007) Short-term and mid-term outcome of isolated symptomatic muscular calf vein thrombosis. J Vasc Surg 46(3):513–519
Ro A, Kageyama N (2016) Clinical significance of the soleal vein and related drainage veins, in calf vein thrombosis in autopsy cases with massive pulmonary thromboembolism. Ann Vasc Dis 9(1):15–21
Wang CJ, Wang JW, Weng LH, Huang CC, Yu PC (2007) Clinical significance of muscular deep-vein thrombosis after total knee arthroplasty. Chang Gung Med J 30(1):41–46
Yoshimura N, Hori Y, Horii Y, Takano T, Ishikawa H, Aoyama H (2012) Where is the most common site of DVT? Evaluation by CT venography. Jpn J Radiol 30(5):393–397
Henry JC, Satiani B (2014) Calf muscle venous thrombosis: a review of the clinical implications and therapy. Vasc Endovascular Surg 48(5–6):396–401
Palareti G, Schellong S (2012) Isolated distal deep vein thrombosis: what we know and what we are doing. J Thromb Haemost 10(1):11–19
Macdonald PS, Kahn SR, Miller N, Obrand D (2003) Short-term natural history of isolated gastrocnemius and soleal vein thrombosis. J Vasc Surg 37(3):523–527
Guias B, Simoni G, Oger E, Lemire A, Leroyer C, Mottier D, Nonent M, Bressollette L (1999) Calf muscle venous thrombosis and pulmonary embolism. J Mal Vasc 24(2):132–134
Ohgi S, Tachibana M, Ikebuchi M, Kanaoka Y, Maeda T, Mori T (1998) Pulmonary embolism in patients with isolated soleal vein thrombosis. Angiology 49(9):759–764
Pham XB, de Virgilio C (2016) Significance of isolated calf vein thrombosis-further evidence. JAMA Surg 151(9):e161799
Wei M, Zhu J, Yi X, Huang Y, Liu F, Hu B (2013) The prevalence of isolated calf deep vein thrombosis in patients with pulmonary embolism. Int Angiol 32(5):465–470
Lautz TB, Abbas F, Walsh SJ, Chow C, Amaranto DJ, Wang E, Blackburn D, Pearce WH, Kibbe MR (2010) Isolated gastrocnemius and soleal vein thrombosis: should these patients receive therapeutic anticoagulation? Ann Surg 251(4):735–742
Baglin T, Douketis J, Tosetto A, Marcucci M, Cushman M, Kyrle P, Palareti G, Poli D, Tait RC, Iorio A (2010) Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient-level meta-analysis. J Thromb Haemost 8(11):2436–2442
Eckenrode G, Baltich Nelson B, Belarmino A, Chen SA, Goel S, Meltzer AJ (2019) Meta-analysis and systematic review of interventional therapy versus anticoagulation for isolated femoropopliteal deep venous thrombosis. J Vasc Surg Venous Lymphat Disord 7(2):272–276
Matharu GS, Kunutsor SK, Judge A, Blom AW, Whitehouse MR (2020) Clinical effectiveness and safety of aspirin for venous thromboembolism prophylaxis after total hip and knee replacement: a systematic review and meta-analysis of randomized clinical trials. JAMA Intern Med 180(3):376–384
Stevens SM, Woller SC, Baumann Kreuziger L, Bounameaux H, Doerschug K, Geersing GJ, Huisman MV, Kearon C, King CS, Knighton AJ, Lake E, Murin S, Vintch JRE, Wells PS, Moores LK (2021) Executive summary: antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest 160(6):2247–2259
Feng W, Wang X, Huang D, Lu A (2021) Ranking the efficacy of anticoagulants for the prevention of venous thromboembolism after total hip or knee arthroplasty: a systematic review and a network meta-analysis. Pharmacol Res 166:105438
Peng G, Wang Q, Sun H, Gan L, Lu H, Deng Z, Sun J, Deng J (2021) Development and prospective validation of a novel risk score for predicting the risk of lower extremity deep vein thrombosis among multiple trauma patients. Thromb Res 201:116–122
O’Toole RV, Stein DM, O’Hara NN, Frey KP, Taylor TJ, Scharfstein DO, Carlini AR, Sudini K, Degani Y, Slobogean GP, Haut ER, Obremskey W, Firoozabadi R, Bosse MJ, Goldhaber SZ, Marvel D, Castillo RC (2023) Aspirin or low-molecular-weight heparin for thromboprophylaxis after a fracture. N Engl J Med 388(3):203–213
Mills RM, Berkowitz RD, Damaraju CV, Jennings LK, Wildgoose P (2012) Initiation of rivaroxaban following low molecular weight heparin for thromboprophylaxis after total joint replacement: the safe, simple transitions (SST) study. Thromb Res 130(5):709–715
Liu Y, Zhu Z, Min M (2021) Value of color ultrasound in the diagnosis of muscular calf vein thrombosis after artificial joint replacement. Chin J Dial Artif Organs 32(04):29–30+34
Runner RP, Shau DN, Staley CA, Roberson JR (2021) Utilization patterns, efficacy, and complications of venous thromboembolism prophylaxis strategies in revision hip and knee arthroplasty as reported by american board of orthopaedic surgery part II candidates. J Arthroplasty 36(7):2364–2370
Bergmark BA, Kamphuisen PW, Wiviott SD, Ruff CT, Antman EM, Nordio F, Kuder JF, Mercuri MF, Lanz HJ, Braunwald E, Giugliano RP (2019) Comparison of events across bleeding scales in the ENGAGE AF-TIMI 48 trial. Circulation 140(22):1792–1801
Tomaselli GF, Mahaffey KW, Cuker A, Dobesh PP, Doherty JU, Eikelboom JW, Florido R, Gluckman TJ, Hucker WJ, Mehran R, Messé SR, Perino AC, Rodriguez F, Sarode R, Siegal DM, Wiggins BS (2020) ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the american college of cardiology solution set oversight committee. J Am Coll Cardiol 76(5):594–622
Chen C, Liu Y, Wu H, Feng J, Li A, Wu Z (2021) The outcome of isolated calf muscle vein thrombosis after open reduction and internal fixation for closed intra-articular distal femur fractures: a prospective cohort study. BMC Musculoskelet Disord 22(1):397
Labropoulos N, Webb KM, Kang SS, Mansour MA, Filliung DR, Size GP, Buckman J, Baker WH (1999) Patterns and distribution of isolated calf deep vein thrombosis. J Vasc Surg 30(5):787–791
Gong H, Huang B, Fu L, Sun C, Chen L (2020) Muscular calf vein thrombosis after total knee arthroplasty. Chin J Sports Med 39(11):863–869
Schwarz T, Schmidt B, Beyer J, Schellong SM (2001) Therapy of isolated calf muscle vein thrombosis with low-molecular-weight heparin. Blood Coagul Fibrinolysis 12(7):597–599
Samama CM, Laporte S, Rosencher N, Girard P, Llau J, Mouret P, Fisher W, Martínez-Martín J, Duverger D, Deygas B, Presles E, Cucherat M, Mismetti P (2020) Rivaroxaban or enoxaparin in nonmajor orthopedic surgery. N Engl J Med 382(20):1916–1925
Mohammady M, Radmehr M, Janani L (2021) Slow versus fast subcutaneous heparin injections for prevention of bruising and site pain intensity. Cochrane Database Syst Rev 6(6):Cd008077
Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W (2008) Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 358(26):2765–2775
Farge D, Frere C, Connors JM, Khorana AA, Kakkar A, Ay C, Muñoz A, Brenner B, Prata PH, Brilhante D, Antic D, Casais P, Guillermo Esposito MC, Ikezoe T, Abutalib SA, Meillon-García LA, Bounameaux H, Pabinger I, Douketis J (2022) international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol 23(7):e334–e347
Turpie AG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, Cushner FD, Lotke PA, Berkowitz SD, Bandel TJ, Benson A, Misselwitz F, Fisher WD (2009) Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 373(9676):1673–1680
Franco L, Giustozzi M, Agnelli G, Becattini C (2017) Anticoagulation in patients with isolated distal deep vein thrombosis: a meta-analysis. J Thromb Haemost 15(6):1142–1154
Tran HA, Gibbs H, Merriman E, Curnow JL, Young L, Bennett A, Tan CW, Chunilal SD, Ward CM, Baker R, Nandurkar H (2019) New guidelines from the thrombosis and haemostasis society of Australia and New Zealand for the diagnosis and management of venous thromboembolism. Med J Aust 210(5):227–235
Funding
This study was supported by: The National Key R&D Program of China (No.2021YFA1102600), National Natural Science Foundation of China (No. 82002293), Science and Technology Planning Project of Guangzhou City, China (Grant No. 202201020495, 202201020481); Guangdong Basic and Applied Basic Research Foundation (Grant No. 2019A1515011647, 2021A1515010693, 2021A1515010294, 2022A1515010256). The funding agency had no role in designing the study, conducting the analysis, interpreting the data or writing the manuscript.
Author information
Authors and Affiliations
Contributions
All authors contributed to the study’s conception and design. Acquisition, analysis and interpretation of data were performed by ZCH and MYC. The first draft of the manuscript was written by ZCH. Critical revision of the manuscript was performed by HS, DL and ZQC. RFM, JX and SQM: final approval of the version, agree to be accountable for all aspects of the work. All authors have read and approved the manuscript.
Corresponding authors
Ethics declarations
Conflict of interest
The authors have no relevant financial or non-financial interests to disclose.
Ethics approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The Human Investigation Committee (IRB) of Sun Yat-sen University approved this study.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Huang, Z., Sun, H., Li, D. et al. Follow-up study of isolated calf muscular vein thrombosis for anticoagulant therapy after primary hip and knee arthroplasty. Arch Orthop Trauma Surg 144, 7–13 (2024). https://doi.org/10.1007/s00402-023-05011-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00402-023-05011-9